| Project/Area Number |
24659566
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
HORI Hitoshi 徳島大学, ソシオテクノサイエンス研究部, 教授 (90119008)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UTO Yoshihiro 徳島大学, 大学院ソシオテクノサイエンス研究部, 准教授 (20304553)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | インターベンショナルラジオロジー（ＩＶＲ） / ボロントレースドラッグ / 中性子 / クルクミン |
|---|
| Research Abstract |
The purpose of this research is to development a boron trace drug with broad molecule pursuit and destructive power by neutron irradiation. We performed the destruction of BSA and glycated BSA as a AGE model using boron-modified crucumin UTX-51 and thermal neutron, and pharmacokinetic analysis of UTX-51 by a chicken egg model. It turned out that UTX-51 destroys BSA and the glycated BSA efficiently at the combined with a thermal neutron. Moreover, it revealed that UTX-51 passing through a blood brain barrier and also being distributed in a brain from the pharmacokinetic analysis. Therefore, UTX-51 is more promising as a boron trace drug, and it was suggested that it can become a candidate for Alzheimer's disease.
|
